Suraksha Diagnostic IPO details Today : Suraksha Diagnostic IPO details Today is Open on [.] 2024 and Close on [.] 2024. Suraksha Diagnostic IPO to Raise 19,189,330 shares (Approx ₹[.] Cr) via IPO. The Fresh issue of [.] shares (Approx ₹[.] Cr) and The Offer For Sale is 19,189,330 shares (Approx ₹[.] Cr).
We have implemented a cluster based ‘hub and spoke’ model which provides greater economies of scale, enables increased consistency in testing procedures, and enhances our brand penetration through our ability to serve more customers in remote areas. Samples are collected across multiple locations within a cluster for delivery to our laboratories for diagnostic testing.
All of our diagnostic centres offer integrated diagnostics services (pathology and radiology tests under one roof) with small and medium centres (“spoke centres”) offering pathology tests and basic and intermediate radiology tests, and large centres (“hub centres”) offering pathology tests, basic and advanced radiology tests.
- Largest diagnostic chain with a dominant position in eastern India well positioned to leverage high growth opportunity for organized diagnostic chains in the fragmented diagnostic services markets in eastern and north-eastern India.
- Track record of profitability and consistent financial performance.
- Integrated diagnostics provider with one-stop solution offering pathology and radiology testing, and medical consultation services.
- Well-invested and technologically advanced clinical infrastructure and trained personnel ensuring high quality and reliable diagnostic services.
- High brand recall and commitment to superior quality driving high individual consumer business share and customer retention.
- Management team with relevant industry experience.
The nature of the diagnostic market in eastern and north-eastern India is fragmented, with presence of many unorganized players and the region has diverse landscapes, including remote and underserved areas, where access to quality healthcare services, particularly diagnostics, is limited. We offer a comprehensive range of 2,300+ tests that cover a range of specialties and disciplines.
Our diagnostic test menu included (a) 788 routine pathology tests ranging from basic biochemistry and hematology to 647 specialized pathology tests such as advanced biochemistry, histopathology, and molecular pathology, and (b) 748 basic/intermediate radiology tests ranging from basic x-rays, USG, and CT scans to 104 advanced radiology tests such as MRI scans and specialized CT scans.
We believe our ability to provide one-stop diagnostic solutions is an important factor in customers choosing us as their diagnostic service provider, helps us in retaining our customers, and sets us apart from our competitors. Our integrated offerings of pathology, radiology and medical consultation under a single roof, enable us to provide comprehensive services to patients and adds to patient convenience.
We aim to provide customers quality, hygienic and reliable diagnostic services at marginally premium yet affordable prices. Our cluster based ‘hub and spoke’ model allows samples to be collected across multiple locations within a cluster for delivery to our laboratories for diagnostic testing, greater economies of scale, enables increased consistency in our testing procedures, and enhances our brand penetration through our ability to serve more customers in under-served areas.
Our flagship central reference laboratory located in New Town, Kolkata, spread over an area of 40,000 square feet, houses a fully automated AI enabled robotic track and also houses liquid chromatography with tandem mass spectroscopy (“LC-MS-MS”), cytogenetics, and next-generation sequencing capabilities.
We use digital pathology and artificial intelligence to report blood tests. All our radiology reporting operate on a digital platform enabling us to report cases from across ourdiagnostic centres reducing turnaround time considerably. We have introduced peer review in all high-end radiology reporting. Our MRI portfolio ranges from 1.5T to 3T. We also offer up to 128-slice CT scans. We believe all of these underscores our commitment to providing high quality and reliable diagnostic services.
Object of the Issue
- Carry out the Offer for Sale of up to 19,189,330 Equity Shares of face value ₹ 2 each aggregating to ₹ [●] million by the Selling Shareholders.
- Achieve the benefits of listing the Equity Shares on the Stock Exchanges.
Our Company Promoters
- Dr Somnath Chatterjee
- Ritu Mittal
- Satish Kumar Verma
Qualitative Factors
- Largest diagnostic chain in eastern India well positioned to leverage high growth opportunity for organized diagnostic chains in the fragmented diagnostic services markets in eastern and north-eastern India.
- Track record of profitability and consistent financial performance.
- Integrated diagnostics provider with one-stop solution offering pathology and radiology testing, and medical consultation services.
- Well-invested and technologically advanced clinical infrastructure and trained personnel ensuring high quality and reliable diagnostic services.
- High brand recall and commitment to superior quality driving high individual consumer business share and customer retention.
- Management team with relevant industry experience.
Comparison of Accounting Ratios with Listed Peer Group Companies
- Suraksha Diagnostic Limited
- Dr Lal PathLabs
- Metropolis Healthcare
- Thyrocare
- Vijaya Diagnostic
Also Read: Senores Pharmaceuticals IPO
Suraksha Diagnostic Company Contact Details
Plot No. DG-12/1, Action Area 1D
Premises No. 02-0327 New Town, Rajarhat
Kolkata 700 156 West Bengal, India
Email: investors@surakshanet.com
Tel: +91 33 66059750
Contact Person: Mamta Jain
Website: www.surakshanet.com
Suraksha Diagnostic IPO Registrar
KFin Technologies Limited
Selenium, Tower B, Plot No. 31 and 32
Financial District, Nanakramguda, Serilingampally
Hyderabad 500 032
Telangana, India
Telephone Number: +91 40 6716 2222/1800 309 4001
Website: www.kfintech.com
Investor Grievance E-mail: einward.ris@kfintech.com
Email ID: sdl.ipo@kfintech.com
Contact Person: M. Murali Krishna
